Looking to expand your partner network with leading companies like Genethon? Consider joining Inpart's global network for free.
News and Trends 18 Dec 2017
British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease
Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […]
